Viatris Clears US Symbicort Hurdle But Loses Key Patent Fight To AstraZeneca

Three US Patents Not Invalid Due To Obviousness; Appeal Planned

 
• By Dean Rudge
  
Gavel
Viatris failed to demonstrate obviousness by clear and convincing evidence • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin